International Pharmaceutical Transparency Act of 2019

[Congressional Bills 116th Congress]
[From the U.S. Government Publishing Office]
[H.R. 5381 Introduced in House (IH)]

<DOC>






116th CONGRESS
  1st Session
                                H. R. 5381

To amend the Federal Food, Drug, and Cosmetic Act to require the label 
 of a drug to list the country of origin of each of the drug's active 
                              ingredients.


_______________________________________________________________________


                    IN THE HOUSE OF REPRESENTATIVES

                           December 10, 2019

Mr. DesJarlais introduced the following bill; which was referred to the 
                    Committee on Energy and Commerce

_______________________________________________________________________

                                 A BILL


 
To amend the Federal Food, Drug, and Cosmetic Act to require the label 
 of a drug to list the country of origin of each of the drug's active 
                              ingredients.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

    This Act may be cited as the ``International Pharmaceutical 
Transparency Act of 2019''.

SEC. 2. COUNTRY-OF-ORIGIN LABELING FOR ACTIVE INGREDIENTS IN DRUGS.

    (a) Misbranding.--Section 502 of the Federal Food, Drug, and 
Cosmetic Act (21 U.S.C. 352) is amended by adding at the end the 
following:
    ``(ee) If it is a drug and its label fails to list the country of 
origin of each of its active ingredients.''.
    (b) Applicability.--Section 502(ee) of the Federal Food, Drug, and 
Cosmetic Act, as added by subsection (a), applies beginning on the day 
that is 6 months after the date of enactment of this Act.
                                 <all>